Last reviewed · How we verify
L608 Liposomal inhalation suspension
L608 Liposomal inhalation suspension is a Small molecule drug developed by Pharmosa Biopharm Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | L608 Liposomal inhalation suspension |
|---|---|
| Sponsor | Pharmosa Biopharm Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L608 Liposomal inhalation suspension CI brief — competitive landscape report
- L608 Liposomal inhalation suspension updates RSS · CI watch RSS
- Pharmosa Biopharm Inc. portfolio CI
Frequently asked questions about L608 Liposomal inhalation suspension
What is L608 Liposomal inhalation suspension?
L608 Liposomal inhalation suspension is a Small molecule drug developed by Pharmosa Biopharm Inc..
Who makes L608 Liposomal inhalation suspension?
L608 Liposomal inhalation suspension is developed by Pharmosa Biopharm Inc. (see full Pharmosa Biopharm Inc. pipeline at /company/pharmosa-biopharm-inc).
What development phase is L608 Liposomal inhalation suspension in?
L608 Liposomal inhalation suspension is in Phase 1.